The Tata Memorial Centre (TMC) is set to enhance its medical infrastructure with the establishment of a 150-bed multispecialty hospital at the Advanced Centre for Treatment, Research, and Education in Cancer (ACTREC) in Kharghar. The facility, which is expected to be completed within three years, has been designed to address non-cancer-related complications affecting major organs such as the heart, lungs, and kidneys. Currently, patients receiving cancer treatment at ACTREC are often required to seek specialized care at other hospitals. To eliminate this challenge, a 12-storey multispecialty facility is being constructed to provide comprehensive treatment within a single institution.
In addition to the new hospital, several initiatives aimed at improving patient care and accommodation are being undertaken. With the support of the Infosys Foundation, Asha Nivas is being developed to offer free or subsidized lodging for 300 patients and their caregivers. This initiative is expected to ensure that families remain close to medical support throughout the treatment process. Further, a dedicated St. Jude’s Children’s Cancer Centre is being constructed, which will provide residential support for 220 pediatric cancer patients and their families. The completion of this 11-storey facility is projected for mid-2025.
A significant expansion is also being made in the treatment of blood cancers. A 400-bed hospital dedicated to the management of both pediatric and adult blood cancers is currently under development. With completion expected by December 2025, the facility has been planned to improve accessibility to treatment for some of the most curable cancers. It has been emphasized by medical experts at ACTREC that specialized care in this field is crucial, as pediatric and blood cancers have high survival rates when treated effectively. This new hospital is expected to strengthen the capacity for high-quality, specialized treatment.
Apart from infrastructural advancements, significant progress in advanced therapies is being pursued at ACTREC. Since 2007, more than 1,100 bone marrow transplants have been performed at the centre. Cellular therapies, including CAR-T cell therapy, are also being expanded to offer cutting-edge immunotherapy for blood cancers. The first CAR-T cell treatment at ACTREC was administered in June 2021 to a child diagnosed with acute lymphoblastic leukemia. The centre is now focusing on broadening the availability of such innovative treatments.
With these expansions, TMC’s role in cancer care and research is being further strengthened. Currently, nearly 1,20,000 new cancer patients are treated annually across TMC’s 11 hospitals located in seven states. Originally established as a research facility, ACTREC has evolved into a major hub for both cancer treatment and innovation. Upon completion of the new developments, the facility will house over 1,000 beds, making it one of the largest cancer hospitals in Southeast Asia.
Share
Tweet
